Table 3 Treatment prescriptions in the migraine cohort
|  | First prescription (N = 165,339) | Second prescription (N = 26,537) | Third prescription (N = 4,937) | Fourth prescription (N = 1,227) | ||||
|---|---|---|---|---|---|---|---|---|
n | (%) | n | (%) | n | (%) | n | (%) | |
Any acute treatment | 155,890 | 94.3 | 18,540 | 69.9 | 1,682 | 34.1 | 233 | 19.0 |
Acetaminophen and/or NSAIDs | 90,605 | 54.8 | 11,114 | 41.9 | 1,090 | 22.1 | 156 | 12.7 |
 Acetaminophen and/or NSAIDs only | 64,018 | 38.7 | 10,375 | 39.1 | 1,022 | 20.7 | 150 | 12.2 |
 + Triptan | 20,211 | 12.2 | 168 | 0.6 | 9 | 0.2 | 1 | 0.1 |
 + Ergotamine | 784 | 0.5 | 27 | 0.1 | 4 | 0.1 | 0 | 0.0 |
 + Preventive treatment | 3,073 | 1.9 | 500 | 1.9 | 52 | 1.1 | 5 | 0.4 |
 + Others | 2,519 | 1.5 | 44 | 0.2 | 3 | 0.1 | 0 | 0.0 |
Triptan | 85,023 | 51.4 | 6,998 | 26.4 | 468 | 9.5 | 48 | 3.9 |
 Triptan only | 51,674 | 31.3 | 5,946 | 22.4 | 408 | 8.3 | 44 | 3.6 |
 + Acetaminophen and/or NSAIDsa | 20,211 | 12.2 | 168 | 0.6 | 9 | 0.2 | 1 | 0.1 |
 + Ergotamine | 187 | 0.1 | 11 | 0.0 | 1 | 0.0 | 0 | 0.0 |
 + Preventive treatment | 9,747 | 5.9 | 802 | 3.0 | 49 | 1.0 | 2 | 0.2 |
 + Others | 23,415 | 14.2 | 239 | 0.9 | 10 | 0.2 | 2 | 0.2 |
Ergotamine | 3,887 | 2.4 | 659 | 2.5 | 138 | 2.8 | 30 | 2.4 |
 Ergotamine only | 2,622 | 1.6 | 565 | 2.1 | 119 | 2.4 | 23 | 1.9 |
 + Acetaminophen and/or NSAIDsa | 784 | 0.5 | 27 | 0.1 | 4 | 0.1 | 0 | 0.0 |
 + Triptana | 187 | 0.1 | 11 | 0.0 | 1 | 0.0 | 0 | 0.0 |
 + Preventive treatment | 185 | 0.1 | 53 | 0.2 | 14 | 0.3 | 5 | 0.4 |
 + Others | 1,080 | 0.7 | 41 | 0.2 | 5 | 0.1 | 2 | 0.2 |
Any preventive treatment | 25,801 | 15.6 | 9,445 | 35.6 | 3,374 | 68.3 | 1,009 | 82.2 |
Anti-CGRP mAb | 29 | 0.0 | 155 | 0.6 | 211 | 4.3 | 178 | 14.5 |
 Anti-CGRP mAb only | 18 | 0.0 | 151 | 0.6 | 206 | 4.2 | 174 | 14.2 |
 + Acetaminophen and/or NSAIDs | 1 | 0.0 | 1 | 0.0 | 1 | 0.0 | 0 | 0.0 |
 + Triptan | 2 | 0.0 | 1 | 0.0 | 1 | 0.0 | 0 | 0.0 |
 + Ergotamine | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
 + Other preventive treatment | 2 | 0.0 | 2 | 0.0 | 3 | 0.1 | 2 | 0.2 |
 + Others | 6 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 0.2 |
Antiepileptics | 7,832 | 4.7 | 2,793 | 10.5 | 1,068 | 21.6 | 284 | 23.1 |
 Antiepileptics only | 3,033 | 1.8 | 2,193 | 8.3 | 963 | 19.5 | 273 | 22.2 |
 + Acetaminophen and/or NSAIDs | 908 | 0.5 | 132 | 0.5 | 20 | 0.4 | 1 | 0.1 |
 + Triptan | 2,265 | 1.4 | 185 | 0.7 | 18 | 0.4 | 0 | 0.0 |
 + Ergotamine | 44 | 0.0 | 12 | 0.0 | 6 | 0.1 | 0 | 0.0 |
 + Other preventive treatment | 331 | 0.2 | 206 | 0.8 | 54 | 1.1 | 7 | 0.6 |
 + Others | 1,251 | 0.8 | 65 | 0.2 | 7 | 0.1 | 3 | 0.2 |
Antidepressants | 3,386 | 2.0 | 1,632 | 6.1 | 715 | 14.5 | 250 | 20.4 |
 Antidepressants only | 771 | 0.5 | 1,189 | 4.5 | 631 | 12.8 | 234 | 19.1 |
 + Acetaminophen and/or NSAIDs | 311 | 0.2 | 96 | 0.4 | 9 | 0.2 | 1 | 0.1 |
 + Triptan | 1,095 | 0.7 | 96 | 0.4 | 11 | 0.2 | 1 | 0.1 |
 + Ergotamine | 24 | 0.0 | 8 | 0.0 | 3 | 0.1 | 1 | 0.1 |
 + Other preventive treatment | 307 | 0.2 | 191 | 0.7 | 54 | 1.1 | 12 | 1.0 |
 + Others | 878 | 0.5 | 52 | 0.2 | 7 | 0.1 | 1 | 0.1 |
Beta-blockers | 1,804 | 1.1 | 671 | 2.5 | 361 | 7.3 | 134 | 10.9 |
 Beta-blockers only | 906 | 0.5 | 539 | 2.0 | 331 | 6.7 | 128 | 10.4 |
 + Acetaminophen and/or NSAIDs | 181 | 0.1 | 43 | 0.2 | 12 | 0.2 | 0 | 0.0 |
 + Triptan | 370 | 0.2 | 26 | 0.1 | 4 | 0.1 | 1 | 0.1 |
 + Ergotamine | 11 | 0.0 | 4 | 0.0 | 3 | 0.1 | 1 | 0.1 |
 + Other preventive treatment | 69 | 0.0 | 42 | 0.2 | 10 | 0.2 | 4 | 0.3 |
 + Others | 267 | 0.2 | 17 | 0.1 | 1 | 0.0 | 0 | 0.0 |
Ca-channel blockers | 14,511 | 8.8 | 4,616 | 17.4 | 1,114 | 22.6 | 182 | 14.8 |
 Ca-channel blockers only | 4,187 | 2.5 | 3,585 | 13.5 | 1,037 | 21.0 | 169 | 13.8 |
 + Acetaminophen and/or NSAIDs | 1,672 | 1.0 | 228 | 0.9 | 10 | 0.2 | 3 | 0.2 |
 + Triptan | 6,015 | 3.6 | 494 | 1.9 | 15 | 0.3 | 0 | 0.0 |
 + Ergotamine | 106 | 0.1 | 29 | 0.1 | 2 | 0.0 | 3 | 0.2 |
 + Other preventive treatment | 325 | 0.2 | 223 | 0.8 | 45 | 0.9 | 7 | 0.6 |
 + Others | 2,206 | 1.3 | 57 | 0.2 | 5 | 0.1 | 0 | 0.0 |